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RET mutations and medullary thyroid cancerI read with interest the report in the Journal of the
Formosan Medical Association by Chang et al1 on RET
mutations in patients with medullary thyroid cancer
(MTC). The authors observed 15 patients with MTC, and
noted that all eight patients with a family history, or
with other phenotypes of multiple endocrine neoplasia
type 2 (MEN 2), had RET mutations (four MEN 2A in
codon 634, two MEN 2B in codon 918, and two others),
whereas no significant RET mutation was found in seven
patients with isolated MTC and no family history or other
endocrinopathies.
RET mutations can occur as a germline event (i.e., RET
mutations occur both in blood and in tumors) in MEN 2A,
MEN 2B, and familial MTC. MEN 2B is usually caused by
mutations in the tyrosine kinase domain (in 95% of cases
involving codon 918, and in 5% codon 883). MEN 2A and
familial MTC mutations affect primarily the cysteine-rich
domain (codons 609, 611, 618, 620, 630, and 634). In MEN
2A, codon 634 is most frequently affected (85%), whereas in
familial MTC the mutations are more evenly distributed
among the various codons.2 In 20-50% of sporadic MTCs,
somatic RET mutations (i.e., RET mutations in tumors but
not in blood) have been found.2
In a phase I trial of cabozantinib (XL184, a VEGFR, MET,
and RET inhibitor), germline and somatic RET genotyping
for the patients with MTC (nZ 37) was performed using
DNA isolated from whole blood (nZ 30) and tumor
(nZ 31), respectively. Three MTC patients had germline
RET mutations, while 23 MTC patients had somatic RET
mutations.30929-6646/$ - see front matter Copyright ª 2011, Elsevier Taiwan LLC
doi:10.1016/j.jfma.2011.09.017It is strange that Chang et al in their study found no
significant RETmutation in seven patients with isolated MTC
without a family history and other endocrinopathies. On
careful reading of the “Patients and Method” section of their
report, I found that only blood or buccal mucosa, not tumors,
were genotyped for RET mutations. It is possible that seven
“isolated” MTC patients had sporadic MTC, not familial MTC;
and that some of them had RET mutations in their tumors.
I think it is important for the authors to comment on this issue
and perhaps reply within the context of the Journal.
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